Armata Pharmaceuticals Inc (ARMP)
XASE:ARMP
Want to see ARMP full AI Analyst Report?
Top Page
Armata Pharmaceuticals
(NYSE MKT:ARMP)
Select Model
Select Model
Rating:42Neutral
Price Target:
$8.50
▼(-26.09% Downside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by weak financial performance (large losses, negative equity, and ongoing cash burn) and soft technicals (below key moving averages with negative MACD). Positive regulatory designations and pipeline progress provide some offset, but financing/liquidity risk remains a key overhang.
Positive Factors
Regulatory & Clinical Momentum
Fast Track designation (and prior QIDP) materially improves regulatory engagement and potential expedited pathways. This reduces late-stage regulatory risk, could shorten time-to-market, and extends exclusivity, strengthening the long-term commercial viability of AP-SA02 if Phase 3 confirms benefit.
Negative Factors
Negative Stockholders' Equity
Persistently negative equity constrains financing options and signals cumulative losses. It elevates dilution and refinancing risk, can complicate partnerships or licensing, and materially reduces financial flexibility needed to fund late-stage trials and commercialization over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory & Clinical Momentum
Fast Track designation (and prior QIDP) materially improves regulatory engagement and potential expedited pathways. This reduces late-stage regulatory risk, could shorten time-to-market, and extends exclusivity, strengthening the long-term commercial viability of AP-SA02 if Phase 3 confirms benefit.
Read all positive factors
Armata Pharmaceuticals (ARMP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$299.93M
Dividend YieldN/A
Average Volume (3M)74.30K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth10.70%
EPS Growth-66831.90%
CountryUS
Employees60
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.77
Shares Outstanding36,710,810
10 Day Avg. Volume71,576
30 Day Avg. Volume74,303
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.04
Price to Sales (P/S)46.41
P/FCF Ratio-8.65
Enterprise Value/Market Cap2.23
Enterprise Value/Revenue226.11
Enterprise Value/Gross Profit313.28
Enterprise Value/Ebitda-4.14
Forecast
1Y Price Target
$17.50Price Target Upside52.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.9
Revenue Forecast (FY)$1.80M
Armata Pharmaceuticals Business Overview & Revenue Model
Company Description
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-bas...
How the Company Makes Money
Armata Pharmaceuticals has historically generated little to no recurring revenue because it is primarily a clinical-stage drug developer and does not sell approved commercial products. To the extent the company generates revenue, it may come from ...
Armata Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.96M | 4.90M | 5.17M | 4.53M | 5.51M | 4.47M |
| Gross Profit | 2.13M | 3.37M | -29.25M | 3.56M | -29.51M | -15.54M |
| EBITDA | -161.45M | -29.69M | -41.11M | -65.45M | -36.05M | -21.92M |
| Net Income | -282.61M | -173.80M | -18.92M | -69.05M | -36.92M | -23.16M |
Balance Sheet | ||||||
| Total Assets | 69.80M | 76.88M | 86.44M | 98.36M | 107.88M | 69.77M |
| Cash, Cash Equivalents and Short-Term Investments | 4.75M | 8.69M | 9.29M | 13.52M | 14.85M | 10.29M |
| Total Debt | 373.67M | 288.02M | 126.52M | 120.37M | 48.81M | 37.99M |
| Total Liabilities | 381.39M | 295.48M | 134.46M | 130.43M | 71.80M | 44.37M |
| Stockholders Equity | -311.59M | -218.60M | -48.02M | -32.06M | 36.08M | 25.40M |
Cash Flow | ||||||
| Free Cash Flow | -24.47M | -26.30M | -39.43M | -55.57M | -34.69M | -24.88M |
| Operating Cash Flow | -23.96M | -25.76M | -37.55M | -47.42M | -32.48M | -23.57M |
| Investing Cash Flow | -506.00K | -542.00K | -1.88M | -8.13M | -2.21M | -1.30M |
| Financing Cash Flow | 16.27M | 25.61M | 34.96M | 53.99M | 44.02M | 25.52M |
Armata Pharmaceuticals Technical Analysis
Negative
11.50
Price Trends
9.89
Negative
9.17
Negative
6.88
Positive
Market Momentum
-0.62
Negative
42.36
Neutral
54.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARMP, the sentiment is Negative. The current price of 11.5 is above the 20-day moving average (MA) of 8.53, above the 50-day MA of 9.89, and above the 200-day MA of 6.88, indicating a neutral trend. The MACD of -0.62 indicates Negative momentum. The RSI at 42.36 is Neutral, neither overbought nor oversold. The STOCH value of 54.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARMP.
Armata Pharmaceuticals Risk Analysis
Armata Pharmaceuticals disclosed 30 risk factors in its most recent earnings report. Armata Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Armata Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $162.48M | 1.47 | 60.96% | ― | -100.00% | ― | |
53 Neutral | $188.12M | -8.52 | -48.20% | ― | 7336.90% | 49.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $60.78M | -4.69 | 76.02% | ― | ― | -13.32% | |
46 Neutral | $38.04M | -3.64 | -53.43% | ― | -100.00% | 63.20% | |
46 Neutral | $51.28M | 1.00 | -560.64% | ― | -32.64% | 56.66% | |
42 Neutral | $299.93M | -1.06 | 162.59% | ― | 10.70% | -66831.90% |
* Healthcare Sector Average
ARMP
Armata Pharmaceuticals
8.17
6.23
321.13%
VERU
Veru
2.37
-3.40
-58.93%
ORMP
Oramed Pharm
3.97
1.75
78.99%
ELUT
Elutia
1.16
-0.60
-34.09%
ADAG
Adagene
3.97
1.89
90.41%
INKT
MiNK Therapeutics
12.20
5.03
70.15%
Armata Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Armata Secures New Loan Amid Wider Quarterly Loss
Negative
May 13, 2026
On May 13, 2026, Armata reported first-quarter 2026 results and outlined plans to advance AP-SA02 into a Phase 3 superiority trial in complicated Staphylococcus aureus bacteremia in the second half of 2026, following FDA Fast Track and Qualified I...
Business Operations and StrategyProduct-Related Announcements
Armata Gains FDA Fast Track for AP-SA02 Therapy
Positive
May 7, 2026
On May 7, 2026, Armata Pharmaceuticals announced that the U.S. Food and Drug Administration granted Fast Track designation to AP-SA02, its intravenously administered multi-phage product candidate for adjunct treatment of complicated Staphylococcus...
Business Operations and StrategyExecutive/Board Changes
Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors
Positive
Apr 27, 2026
On April 27, 2026, Armata Pharmaceuticals announced that Daniel B. Gilmer, Ph.D., a senior commercial executive at Pfizer, has joined its Board of Directors effective April 24, 2026. His appointment brings extensive experience in scientific discov...
Shareholder Meetings
Armata Pharmaceuticals Sets Timeline for 2026 Annual Meeting
Neutral
Apr 2, 2026
Armata Pharmaceuticals has scheduled its 2026 annual meeting of stockholders for June 11, 2026, at 8:30 a.m. Pacific Time at its principal executive offices in Los Angeles, California, with the meeting date and venue potentially subject to change ...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Armata Highlights AP-SA02 Progress Amid Earnings Release Delay
Positive
Mar 19, 2026
On March 19, 2026, Armata Pharmaceuticals said it will delay releasing its fourth-quarter and full-year 2025 financial results while it completes its reporting, but still expects to file its annual report by the March 31 deadline. At the same time...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy
Positive
Feb 23, 2026
On February 23, 2026, Armata Pharmaceuticals announced that the U.S. Food and Drug Administration granted Qualified Infectious Disease Product designation to AP-SA02, its intravenous multi-phage candidate for adjunct treatment of complicated Staph...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.